Target- |
MechanismVitamin K antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date31 Jul 1944 |
100 Clinical Results associated with The University of Manchester Conferences Ltd.
0 Patents (Medical) associated with The University of Manchester Conferences Ltd.
100 Deals associated with The University of Manchester Conferences Ltd.
100 Translational Medicine associated with The University of Manchester Conferences Ltd.